Shares of Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) surged in pre-market trading as the company raised its full-year 2023 adjusted non-GAAP earnings per share (EPS) guidance. 

The new estimated range of $4.40 to $4.70 has been raised from the previously disclosed range of $4.20 to $4.53, outpacing the consensus EPS estimate of $4.26 for the period.

$EGRX is currently trading at $19.18, reflecting an increase of $0.58 (+3.12%) in pre-market 

In other news, Allarity Therapeutics, Inc. (Nasdaq: ALLR) and FivepHusion have joined forces through a Clinical Collaboration Agreement, aimed to advance the clinical development of Deflexifol, a potential treatment for solid tumors.

This collaboration involves the use of Allarity's drug-specific DRP companion diagnostics, including the validated DRP-5FU companion diagnostic. These diagnostics will aid in potentially selecting patients for enrollment and treatment in clinical trials of Deflexifol, both as a monotherapy and in combination with other drugs.

The financial terms of the deal are undisclosed. 

$ALLR surged by $0.68 (+25.56%) to $3.34 in pre-market trading after the announcement.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)